This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
Operator
Good morning and welcome to the BioXL Therapeutics second quarter 2023 financial results conference call. At this time all participants are in a listen only mode. If during the conference you require operator assistance please press star zero on your telephone keypad. After the presentation there will be a question and answer session. If you would like to register a question you may press star one on your telephone keypad. Just to remind everyone, certain matters discussed in today's conference call and or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and or the future financial or business performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements. Risk factors that may affect future results are detailed in the company's annual report on Form 10-Q for the quarter ended March 31, 2023, which can be found at www.bioexceltherapeutics.com or on www.sec.gov, and which will be updated in its quarterly report on Form 10-Q. for the quarter ended June 30th, 2023. As a reminder, today's conference is being recorded. Joining us on today's call are Dr. Vimal Mehta, Chief Executive Officer, Richard Steinhardt, Chief Financial Officer, Matt Wiley, Chief Commercial Officer, Dr. Rob Reisinger, Chief Medical Officer of Neuroscience, Dr. Vince O'Neill, Chief R&D Officer of Oncas Excel Therapeutics, and Dr. Frank Yacca, Chief Scientific Officer. It is now my pleasure to turn the call over to Dr. Amedda, the CEO and founder of BioExcel Therapeutics. Please go ahead.
Vimal Mehta
Thank you, operator. Welcome, everyone, and thank you for joining our call today. Before we begin, I first want to say that the company was dismayed and frustrated by our recent discovery of certain investigator misconduct that occurred during our Tranquility II trial. This summer has not progressed as we had anticipated, and we plan to make significant changes to our entire business structure. While I'm deeply disappointed, I'm more determined than ever to continue developing our drug candidates and put Biaxial Therapeutics back in a position to accomplish its core mission. Now, I will start by covering our strategic reprioritization and how it is designed to position us for success going forward. In addition, I will share as much information as I can about the status of our Tranquility Program in Alzheimer's associated agitation. Six years ago, we founded Biocell Therapeutics with a clear mission to build a uniquely disruptive biopharmaceutical model using AI approaches to bring transformative medicines to patients. We believe we have fulfilled this mission with the approval and launch of Egalme and with our programs in the late stage of clinical development. We are now taking the necessary steps across the business to strengthen our ability to advance our land and expense strategy. Specifically, we are taking clear, well-defined, and decisive actions in three areas. First, let's discuss our commercial reprioritization. We landed with EGALMI's approval in the institutional setting we are now shifting resources to the expand aspect of our market strategy into what we believe is a potentially more promising retail pharmacy and outpatient setting. This shift is largely due to the fact that the hospital setting proved to be more difficult to penetrate than we originally anticipated, particularly in a challenging post-COVID environment. However, we remain committed to making Egalme available to patients in the institutional setting. We began deploying a contracting effort with large hospitals, healthcare systems, and integrated delivery network prior to our reprioritization and have been pleased to see it achieve some initial success with increased demand from existing hospital customers and large health systems. In fact, our Q2 revenues doubled from Q1 largely due to this contracting strategy. Therefore, we will now broadly adopt it. As part of this action, we plan to reduce our total workforce from approximately 190 to 80 employees over the next several months. The majority of these reductions will be in the commercial organization To help us build toward potential labor expansions and to support EGALMI, we will maintain a core 12-member team from market access, commercial operations, sales, and trade functions. This decision to reduce our workforce was extremely difficult for the management team and the board, but was necessitated by a variety of market and business factors. I'm grateful to all of our employees who made many contributions to our company. We are committed to providing support to those impacted as they transition from the company. The second part of our business transformation involves shifting our development focus to high potential education market opportunities for BXEL 501. In bipolar disorders, schizophrenia, and Alzheimer's disease, We firmly believe this drug has the potential to have a positive impact on patients and caregivers and address a significant unmet medical need. For example, 23 million episodes of bipolar schizophrenia-related agitation occur annually in the U.S. In the at-home setting, in addition, 100 million Alzheimer's-related agitation episodes occur every year in the U.S. Importantly, more than 80% of these patients are in a residential setting, and episodes here represent more than half of the total episode volume. We are motivated to develop 501 to address the needs of these patients. We have developed a comprehensive plan for our Tranquility program in Alzheimer's associated agitation. In June, we announced positive top-line data from Tranquility 2. This was a uniquely complex trial requiring mobilization of clinical teams whenever an agitation episode occurred. We were pleased that our top-line data showed that we met our primary endpoint with the 60-megagram dose with 501 demonstrating a statistically significant 39% greater reduction in PEC score from baseline compared to placebo at two hours. We also met a key secondary endpoint with a statistically significant reduction in agitation symptoms versus placebo, as measured by PEC score change from baseline at one hour with 60 microgram dose. 501 was well-tolerated. with no drug-related serious adverse events over trial duration. As we disclosed in an 8-K filing, there were issues related to a principal investigator at a Tranquility II clinical site. The conduct by this PI was unacceptable and extremely unfortunate. We are investigating the issue and, for example, have already initiated an audit by an independent third party of the data from the PI's clinical site. In addition, we have requested a meeting with the FDA to discuss our entire Tranquility Program. This will include both Tranquility 2, Tranquility 3 clinical trials, the data audit, and the data package that may be required to support submission of an SNDA sequence. seeking approval of 501 for the acute treatment of agitation in mild to moderate dementia patients with probable Alzheimer's disease. We hope to have an update on the Tranquility Program, including the audit and FDA meeting by the end of the year. Regarding Tranquility III, we paused enrollment after early trial data showed a much higher background frequency of agitation episode than originally expected. It appears that this patient population may be better suited for a chronic treatment of agitation while our focus is on developing 501 as acute treatment of Alzheimer's agitation. As a reminder, we have breakthrough therapy designation for the acute treatment of agitation associated with dementia. In parallel, we are advancing our serenity program for the at-home acute treatment of agitation associated with bipolar disorders or schizophrenia. In May, we reported top-line results from Serenity 3 Part 1. We evaluated patients in Part 1 in a monitored medical setting as surrogates for the at-home setting. The trial assessed the safety and efficacy of 60-megagram dose of BXCL501 which is half of the lowest approved dose of Vicalme using the same primary and secondary endpoint as in the CINITY1 and 2. While we believe the data suggests the potential for 501 to be effective in a monitored medical setting with 60-microgram dose, we did not meet the primary endpoint or mean change in PEC score at two hours. However, the 60-microgram dose was well-tolerated and demonstrated favorable safety results, including proportionately fewer adverse events compared to those observed during serenity 1 and 2, which evaluated the approved 120 microgram or 180 microgram doses. We believe these safety results support the potential for at-home use. We are now conducting Serenity 3 Part 2. It is a 12-week study to evaluate the safety of a 60-microgram dose of BXL501 with an optional 60-microgram dose. To identify a dose to potentially provide an optimal balance between the safety and efficacy in the at-home population, we performed pharmacokinetic and pharmacodynamic modeling that suggested that use of an 80-microgram dose or BX501 could provide this balance. We believe the evaluation of an 80-microgram dose is further supported by our previous clinical experience with this dose during our Phase 1B trial in schizophrenia patients with agitation. We plan to meet with the FDA to discuss the 80-microgram dose and a protocol amendment to the ongoing Serenity 3 Part 2 study. The primary objective of Part 2 is to describe the incidence of treatment-emergent adverse events. The primary endpoint is a comparison of serious adverse events and treatment-emergent adverse events as compared to placebo. And the secondary endpoints include a number of efficacy assessments. Turning to our major depressive disorder program, we reported positive top line results from the phase 1B multiple ascending dose trial in May. As part of our reprioritization effort, we will pause this program. To augment our clinical development team, Dr. Vince O'Neill, who is currently serving as head of R&D for OncoseXL, will play a broader role in our neuroscience development. Vince has been with the company since the IPO in 2018 and has extensive pharmaceutical clinical development experience. Vince played an instrumental role in Serenity 1 and 2 trials, along with our chief medical officer, Dr. Rob Riesinger, that resulted in the approval of Egalme and the successful human proof of concept trials for 701 in our oncology program. Dushan Kostic, our head of medical affairs, will play an important role in developing clinical and medical strategies of 501 to support commercialization of any potential indications. He has more than two decades of pharmaceutical industry experience in neuroscience. This includes clinical development and commercialization of leading drugs such as Ablify, Invega, Ablify, Mantenna, and Rixalty. We have also initiated a search to expand our board of directors to strengthen clinical development expertise. The third part of our business transformation involves prioritizing AI-driven innovation to strengthen our neuroscience clinical development. Our unique integration of data science, clinical expertise, and commercialization gives us a powerful and distinct competitive advantage in building a robust R&D pipeline. We are truly excited about our clinical development initiatives and pipeline candidates, including VXL502. We look forward to highlighting these developments at an R&D event we plan to host later this year. We also plan to spotlight our next generation AI platform capabilities for identifying, and re-innovating late stage drug candidates and introduce BXEL 503 and 504. In summary, this is challenging yet transformative period for our company. We are taking swift and decisive steps with the goal of putting the company in the best possible position for future success. We have received interest from potential corporate partners However, it is far too early to know what, if any, form such a transaction could take. We are passionate about our goals and remain committed to delivering long-term value to shareholders. Now, I will turn the call over to Rich, who will discuss our second quarter financial results.
Biaxial Therapeutics
Thank you, Vimal. Thank you, Vimal. Our second quarter 2023 financial results are as follows. Net revenue of the GALMI was approximately $457,000 for the quarter. Research and development expenses were $27 million for the second quarter of 2023, compared to $17.9 million for the same period in 2022. The increased expenses were primarily attributable to increased clinical trial expenses for Serenity III and Tranquility II. Selling general and administrative expenses were $25.9 million for the second quarter of 2023, compared to $18.4 million for the same period in 2022. The increased expenses were primarily attributable to an increase in personnel and related costs to support the commercialization of El Gami. While Excel Therapeutics had a $53.5 million loss for the second quarter of 2023, compared to a net loss of $37.7 million for the same period in 2022. The loss for the quarter included approximately $6.1 million in non-cash stock-based compensation. Cash and cash equivalents totaled $127.5 million as of June 30, 2023. As noted, the company is undertaking a strategic reprioritization that includes a reduction in the workforce of more than 50%, which is expected to reduce expenses significantly. In the absence of additional capital becoming available, the company, under the strategic financing agreements or otherwise, the company estimates that its current cash and cash equivalents will last through mid-2024. The company's previously disclosed cash runway projection assumed a full utilization of its strategic financing agreements of $155 million with Oak Tree Fund Administration and Qatar Investment Authority. Based on recent events, the company is not likely to be in a position to meet the milestones required to access the additional capital under the financing agreements. The company is exploring multiple ways to extend its cash runway and is already in discussions with its strategic financing partners to amend the agreements. Successful modification of these agreements could extend the company's cash runway. Finally, with regards to ONCOS Excel, we are currently examining strategic alternatives, including strategic partnerships or financing. Now I'd like to turn the call back to Vimal.
Vimal Mehta
Thank you, Rich. We would now like to open the call for questions. Operator?
Operator
At this time, we'll be conducting a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Our first question today comes from Greg Harrison of Bank of America. Please proceed with your question.
Greg Harrison
Hey, good morning. Thanks for taking the question. How are you thinking about the outlook for the company with this restructuring? And how do you think investors should think about the story at this point?
Vimal Mehta
Good morning, Greg. This is Vimal. I'm very excited about the outlook for our business. As I shared earlier, we are laser focused on the at-home opportunities for BXL 501. Specifically, the two value drivers for 501 are serenity program for schizophrenia and bipolar associated agitation, and our tranquility program for Alzheimer's agitation. We landed with Egalme in the institutional setting. We are now shifting resources to expand into a potentially more promising retail pharmacy and outpatient setting. We also look forward to highlighting our pipeline with BXEL 502 update at R&D day by the end of this year.
Greg Harrison
Got it. That's helpful. And one more, if I can. Could you give us some more color on why you made the decision to shift focus to the at-home setting and away from institutional medical setting?
Vimal Mehta
We are shifting our focus from the institution setting to the retail slash at-home market due to the market and business factors we shared in our call. The hospital setting was more difficult to penetrate than originally anticipated, particularly in a challenging post-COVID environment. It is important to note that we will continue to make Egalme available to our hospital customers through a more targeted contracting effort and small core team. We are committed to bringing Egalme to current and future patients and their families for current indication and for new indications.
Greg Harrison
Thank you for taking the question.
Operator
The next question is from Colin Bristow of UBS. Please proceed with your question.
Colin Bristow
Hey, good morning. And I just wanted to pass on, well done on this reprioritization. You know, tough decisions, but I think they had to be done. And maybe first question is, And just kind of picking back off the prior ones, could you outline how you see the market opportunities for Agami now that you're shifting the focus to the at-home setting? And how should we think about that, specifically from a market opportunity point of view? And then secondly, and I think this is the most common question we're getting from investors, is just updates on the timing of first the external audit. I think I heard you say by the end of the year, but any more colour you can give with where you are in this process would be great. And then on the second part of that, it's just timing regarding feedback from FDA. I know you've requested anything, but when do you expect this to occur, and have you had any sort of interactions or feedback around this data issue? Thank you.
Vimal Mehta
Good morning, Colin. Regarding your question about the Tranquility Program update, as I stated in my earlier remarks, that we expect to have updates or hope to have the update by the end of the year. Independent audit is in progress. We have requested a meeting. Once we have the meeting, we will have a clarity. What is the data package required to file an SNDA? And that will be a good time to provide an update on the Tranquility Program. I just would appreciate if you can come back to your first question that you had asked so that we can address that.
Colin
Yeah, so I think it's about... My first question was... Good morning, Colin. It's Matt. How are you?
Colin Bristow
I was just checking. You heard it, right?
Colin
I did, yeah. So the question about the market opportunity switching from the hospital setting to the at-home setting. Keep in mind that there are 23 million episodes in the at-home setting. One of the things that we accounted for in our models as well is that we would capture many of the patients that wind up in the emergency department in the at-home setting as well. And given the market research that we've conducted, we recognize the unmet need in the home setting is quite significant. It's under-recognized and under-diagnosed, but the patients certainly see value here. And they indicated that both they and their caregivers would use this product profile for BXDL501 in 80% of their episodes. So we feel that the market conditions for the at-home setting is quite favorable, and we look forward to bringing the drug to those patients.
Colin Bristow
Great. Thank you.
Operator
The next question is from Sumant Kulkarni of Canaccord. Please proceed with your question. Good morning. Thanks for taking my question.
spk12
So per your breakthrough therapy designation status, how exactly does the FDA define acute treatment of agitation in terms of number of episodes or instances of film usage per month? Along those lines, do you think the current pricing of $105 per film is appropriate or a strategic misstep for the convenience of at-home use? I'm asking because of two factors. First, even if one were to hit the annual specialty tier of roughly $10,000 per year for pricing on a gross basis, that would translate to a patient using 100 films a year. And makers of chronic treatments of agitation enjoyed significantly higher market caps or buyout values, but pricing assumptions there were much higher as well.
Colin
So let me – I'll address the price question and the number of episodes. You know, first and foremost, we did conduct research when we established our launch price in both bipolar, schizophrenia, and the at-home setting, and also in ADA. And what we found is that for episodic treatment, there was appetite in the market for that price point. Certainly, what we see is the volume of episodes in the mild Alzheimer's dementia patients is roughly three a month, and that can escalate further as they become more moderate. But we also recognize that 81% of the ADA people are either in an at-home setting or an ALS setting, which is akin to an at-home setting, and represent over 50% of the total volume of agitation episodes. And that doesn't preclude 501 from being used in episodic breakthrough
spk12
Got it. And then does your new cash runway include the potential to redo Tranquility 2 in case the FDA says you will not be able to file on just what you have currently?
Vimal Mehta
We are not speculating on that. We are doing an audit, and we want to meet with the FDA and get the feedback. Then we will be able to comment on it.
Operator
Thanks. I'll hop back in the queue. The next question comes from Ram Savaraju of HC Wainwright. Please proceed with your question.
Rob
Hi, thanks very much for taking my question. I just wanted to revert back to the formulary wins that you had previously announced that you were previously engaged in pursuing in the institutional setting and wanted to ask how that is affected, if at all, by your reprioritization here into the at-home setting. To what extent could we potentially expect you to be able to capitalize on the formulary wins that have already happened in the institutional setting and along what trajectory? And also, if you could comment at all on how you expect promotional activities to be different in the at-home context versus the institutional context. Thank you.
Colin
Sure. So first of all, we reported out that we had over 185 formulary wins, P&T wins to date. We're still accumulating those wins at a win rate of over 65%. In fact, we had three wins on Friday. And so we would expect that the 650 or so hospitals that are still scheduled to vote will continue with that process. And assuming that we continue to accrue these hospitals, we will reach out to them through medical affairs activities, through market access activities, contracting, and certainly support them with trade and distribution to ensure that they can access the drug and utilize it. The medical affairs support will obviously be really important in helping them determine how to develop protocols and pathways, so that planning is in place as well. The promotional activities for the at-home market is a little bit different because you are educating physicians and patients at the same time. As you know, patients can be motivated to ask for prescription drugs, so that would be part of the plan as well, and then through sampling and contracting with PBMs. And these are activities that the contracting with PBMs and state Medicaid Those are activities that may be accomplished prior to even FDA approval, considering we have a drug on the market today. So those are activities that we're planning out to get ahead of that potential approval, and more to come on the actual market entry strategy in months to come. Thank you.
Operator
The next question is from Yatin Seneva of Guggenheim Partners. Please proceed with your question.
Yatin Seneva
Hey, guys. Thank you for taking my question. The first question is on the Alzheimer's disease agitation. I understand you will meet with the FDA and try to get their feedback on trend quality two and one. Can you just talk about what generally is the ICA guidelines for an indication like this? What sort of Exposure, duration of exposure is needed from a regulatory perspective for a disease that affects millions of people. It seems like you are sort of stopping Tranquility 2. It's still not clear to me if Tranquility 1 and 2 combined is enough for you to get an approval. So that's one, basically just help me understand the path forward for Alzheimer's disease agitation as you understand. The second is, it seems like on the R&D day, you're going to talk a little bit about the 502. Just curious, you know, if you can highlight a little bit there. And then, you know, in terms of the cash runway, maybe help us understand how should we model it going forward? Where exactly are you putting cost? You know, how many of the sales rep are you still going to have? So, yeah, so these three questions. Thanks.
Vimal Mehta
Thank you, Yatin. First question regarding the Tranquility Program. Rob will answer what our plans are.
Yatin
Yeah, so let me be clear. We paused the trial because the early data in Tranquility III indicated that the patient population may be better suited for chronic as opposed to episodic therapy. And as you know, our focus is on the episodic treatment. in line with our breakthrough therapy designation by FDA for episodic treatment. We have decided to pause the trial in order to discuss this issue with the FDA at an upcoming meeting, and we'll be able to provide more guidance on that once that meeting occurs. We do expect at that meeting to discuss both the auditing and the Tranquility II results. And at that point, we'll be able to provide more guidance at the end of the year with regard to what will be necessary for filing an SNDA package.
Vimal Mehta
Yati, regarding your second question, I will pass it on to Frank for 502 .
Yati
I'm excited about our emerging pipeline development candidates, especially BXCL502. We really are looking forward to an upcoming R&D day where we'll present our progress with this molecule, in particular its development, but also discuss some unique indications of interest. Secondly, We will discuss our next generation AI platform. This has evolved considerably from the first time we did our R&D day two years ago. The capabilities have been enhanced for identifying and re-innovating late-stage opportunities. And we'll also discuss some candidates for additional pipeline entries, such as BXCL 503 and 504. So it'll be a very interesting day.
Vimal Mehta
So regarding your third question, Yati, related to the cash runway, Richard will address it.
Biaxial Therapeutics
Sure, Yati. So the reprioritization that we're working on now will extend the cash runway by reducing our burn significantly. And we're also working on various other options to extend the cash runway, which includes working with our strategic partner. As we said, the goal is to get the company to about an $80 million go-forward annualized burn rate, and that's what we're working towards. In terms of the market, we'll reduce that. The market access team will be a core group of market access teams to work through the commercial sector.
Operator
The next question is from Greg Suvazende of Mizuho Securities. Please proceed with your question.
Greg Suvazende
Good morning. This is Richard for Greg Suvazende at Mizuho. So just two questions for me is, one, just following up from The question, how do you expect the split between R&D and SGMA going forward? And then two, for the EGAUMI opportunity and sales, how should we be melding that on a go-forward basis now that your primary focus is on the at-home setting? Thank you.
Biaxial Therapeutics
So in terms of the commercialization, it's going to be a small core team of about a dozen people. So that will reduce our SG&A expenses pretty dramatically, you know, moving forward. Our R&D expenses should go down. Remember, in the first half of the year, we had Serenity 3 and Tranquility 2 fully implemented, and that's what caused the increase in expenses in the first half of 2023.
Colin
And Richard, regarding your second question on modeling, we've never provided guidance on agami sales. And so I think the way to think about this is by reducing our headcount in commercial to 12, it limits our ability to go out and prospect the way that we had in targeting the 1,700 hospitals. We will continue to support through contracting efforts and through trade and distribution on both our existing customers and those that choose to come online and approve a call me through formulary. We will support them in the same way. So that may help you, but I can't give guidance beyond that.
Operator
The next question is from Robin Kronoskis of Truist Securities. Please proceed with your question.
Robin Kronoskis
Hi, this is Alex for Robin. Can you remind us what the approximate market opportunity is, the breakdown for dementia setting between assisted living facility versus nursing home, and what are the getting factors to a government uptake on the assisted living facility?
Colin
So as I think we've communicated previously, there are 100 million episodes total. Better than 80% of the patients with Alzheimer's dementia, I mentioned this earlier in the call, are in either the at-home setting or the ALF setting. And I don't have a specific breakdown for you here, but certainly something I can communicate later as we get closer to market entry disclosure. Better than 50% of the episodes are in those settings, and we feel that that allows us to price the drug as an episodic drug as opposed to pricing it as a chronic drug, and certainly can be used episodically in any setting. So we think that the TAM still holds at 100 million episodes.
Operator
The next question is from Corinne Jenkins of Goldman Sachs. Please proceed with your question.
spk16
Hi, this is Omari on for Corinne Jenkins. So first, what do you view as your best options to further expand runway beyond mid 2024? And then second question is if the FDA requires an additional study, will they have to start, uh, would you have to start a completely new trial with the same population in 2022?
Vimal Mehta
Hi, this is Vimal. Regarding our cash runway extension, as Richard has already outlined, our cash runway is mid of 2024, and that's obviously predicated on what clinical trials we will be executing on. In terms of our options to extend that cash runway, we have multiple opportunities. One is working with our strategic partner, which Richard has already outlined, who are our financing partners. There is interest developing in these programs by other corporate partners. We are looking into that. And in addition, we have some core assets that we can monetize and capitalize to extend our cash runway. So good news is that we have multiple opportunities to extend our cash runway and achieve meaningful clinical milestones.
Yatin
So let me handle if the FDA has to, another study at this point, is premature to discuss whether another study is required, but in terms of whether that study would be ALF or just at home, again, we certainly make that decision upon consultation with the FDA, and we'll be providing that update later this year.
Vimal Mehta
I think I'd just like to add, on top of what Rob said, we are a pioneer in developing episodic medication to treat agitation. We are learning from the data, from the science, from the clinical outcome that we are observing. We never, or FDA, never expected that we will have so many episodes observed in the nursing home setting. So we are taking that information back to the FDA and designing a program what makes most sense. Does it make sense to have ALF and home setting as episodic? and whatever is needed to put together that package. And would it make sense to go back later on and evaluate the nursing home as a more chronic option? Because I'd like to remind everyone, our breakthrough therapy designation is in for acute treatment of agitation, and we believe mild to moderate probable Alzheimer's disease population is a relevant one so far what we have observed.
Rob
Okay, thank you.
Operator
The next question is from Samir Devani of RX Securities. Please proceed with your question.
Samir Devani
Hi, guys. Thanks for taking my questions. Most of them have been asked already, but I've got a couple. I guess the big question for me, is it realistic for you guys to market directly to generalist physicians for the at-home setting? Isn't that really more the domain of Big Pharma? And have you thought about just doing a partnership deal around Igalmi to address that and reduce the cash burn? And then I guess the second question is just really out of interest. How many agitation episodes were you seeing in Tranquility 3 in the nursing home setting? Thanks very much.
Colin
So I'll take the first question. Good morning. So when we think about the at-home setting for bipolar and schizophrenia, there are roughly 7,000 to 8,000 psychiatrists that either diagnose or actively manage the therapeutic treatments for those patients. So we feel that we would be very well positioned to access that market. As it relates to Alzheimer's dementia agitation, these patients are managed From a top-line perspective, by about 65,000 physicians in the United States, about 30,000 of those would be of interest to us. Those 30,000 are additionally making the diagnosis and treatment evaluation for these patients. Now, of those, there are somewhere between 3,000 to 4,000 that are specialists of interest, but the primary care opportunity or the generalist opportunity, as you described, we would either have to partner with a CSO a potential partnership with a larger pharmaceutical company, or permutations of all three of those. And so, that market entry strategy is not yet that clearly defined, but we're working through those problems for those potential opportunities, I guess, at this time.
Vimal Mehta
So, Samir, regarding how many episodes we observed, I will let Rob answer that.
Yatin
So there are patients continuing in the trial at this point, and they continue to have episodes, so the number is accruing. It's hard to say it on a given day, so I think the best way to describe it would be to say it's regular, and it is greater on an individual basis than what we reported in our Tranquility II results. And this is exactly why we're discussing it with the FDA, so that we have a clear path forward for episodic treatment of acute episodes. And we'll have that guidance at the end of the year.
Samir Devani
Thanks very much.
Operator
The next question is from Khabiz Yazi of Jefferies. Please proceed with your question.
Rob
Good morning, team. What are the proposed features that are going to be in the protocol amendment for Serenity 3 Part 2? What are the kind of key secondary efficacy assessments that would be valuable? And then maybe on your strategic financing partnerships, what modifications to your credit agreement and RIFA would enable you to access capital earlier and be attractive to your partners? Thank you.
Yatin
So we are finalizing that amended protocol. The secondary measures have to do with a variety of different, we'll call them perspectives on efficacy. And once we have the meeting with the FDA, I think it will be much easier to describe the entire study and the details.
Vimal Mehta
Did it answer your question? Because what we are saying is now we have selected a dose, 80 micrograms, based on our pharmacokinetic pharmacodynamic modeling, as we were expecting. And now it's a matter of modifying protocols submitting to the FDA, and then we will be in a position to initiate the study. As Rob has said, the primary is safety. and then efficacy trends as we measure over a 12-week period. So that's what will be the outcome we will be looking from that time.
Rob
Yes, thank you, Jamal.
Vimal Mehta
Regarding your next question, modification on the credit agreement, as Richard has mentioned, that we are in active discussions, and as we make progress, we'll provide an update.
Rob
Thank you very much. Appreciate it.
Operator
There are no additional questions at this time. I'd like to turn the call back over to Dr. Mehta for closing remarks.
Vimal Mehta
Thank you, everyone, for joining us today. We are excited about our path forward through this strategic reprioritization and look forward to sharing updates on our progress. Thank you for your continued interest in BioXcel Therapeutics, and have a great day.
Operator
This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.
Disclaimer